U.S. Water Services, Inc. v. Novozymes A/S
120 F. Supp. 3d 861
W.D. Wis.2015Background
- U.S. Water Services owns patents ('137 and '399, both claiming priority to an earlier '244 application) that teach adding the enzyme phytase to ethanol processing fluids to break down phytic acid and thereby reduce insoluble deposits (fouling) in ethanol plant equipment.
- Defendants Novozymes sell a phytase-based product (Phytaflow); U.S. Water alleges indirect infringement through customers who use phytase in ethanol plants.
- Two prior-art references are central: WO 01/62947 (Veit) and U.S. Patent No. 5,756,714 (Antrim), each disclosing use of phytase in fermentation/starch treatment, including overlapping dosage, temperature, and pH ranges.
- The parties disputed claim scope (notably whether pH must be ≥4.5 “at all times” and whether reduction must be achieved without acids), and the court construed “during” to mean “at some point” and the “substantially without the addition of an acidic compound” limitation to mean reduction is accomplished substantially by phytase rather than by acid+oxidizer or acid+UV.
- Novozymes moved for summary judgment of invalidity (anticipation) and alleged inequitable conduct based on nondisclosure of related ChemTreat litigation during prosecution; U.S. Water moved for summary judgment on inequitable conduct.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Anticipation/Validity of asserted claims | U.S. Water: its claims cover a new, nonobvious use (deposit reduction) and are not anticipated because Veit/Antrim do not disclose the claimed purpose and, per its expert, prior art may not produce the claimed result in a beer column | Novozymes: Veit and Antrim expressly disclose each claim element (adding phytase, dose, temperature, pH ranges, breaking down phytic acid, and not using acid) and inherently disclose that breaking down phytic acid reduces deposits; thus claims are anticipated under 35 U.S.C. § 102 | Court: Grant summary judgment to Novozymes — Veit and Antrim expressly/inherently disclose every claim element; deposit reduction is the natural result of the disclosed phytase treatment, so claims are anticipated |
| Claim construction (two contested terms) | U.S. Water: “during” means “at some point”; disputed acid limitation needs only plain meaning or means reduction is substantially by phytase | Novozymes: “during” means “at all times”; acid limitation precludes any use of acidic compounds at any time | Court: Adopted U.S. Water’s constructions — “during” = at some point during production; acid limitation = reduction accomplished substantially by phytase (does not preclude all acid use) |
| Inequitable conduct (failure to disclose ChemTreat litigation) | U.S. Water: omission was not material and not done with deceptive intent; any litigation facts would not have changed prosecution outcome | Novozymes: patentees withheld material litigation facts demonstrating prior estoppel and knowingly sought broader claims; that nondisclosure was deceptive and but-for material | Court: Grant summary judgment to U.S. Water — Novozymes failed to show by clear and convincing evidence either but-for materiality or that deceptive intent was the single most reasonable inference |
Key Cases Cited
- Phillips v. AWH Corp., 415 F.3d 1303 (Fed. Cir.) (claim construction focuses on the intrinsic record)
- King Pharm., Inc. v. Eon Labs, Inc., 616 F.3d 1267 (Fed. Cir.) (anticipation requires each claim limitation in a single reference; inherent disclosure principles)
- Schering Corp. v. Geneva Pharm., 339 F.3d 1373 (Fed. Cir.) (inherent anticipation doctrine)
- Bristol-Myers Squibb Co. v. Ben Venue Labs., 246 F.3d 1368 (Fed. Cir.) (new results of known processes are not patentable when inherent)
- Perricone v. Medicis Pharm. Corp., 432 F.3d 1368 (Fed. Cir.) (prior art range overlap can anticipate claimed ranges)
- Therasense, Inc. v. Becton, Dickinson & Co., 649 F.3d 1276 (Fed. Cir.) (inequitable conduct requires but-for materiality and specific deceptive intent)
- MEHL/Biophile Int’l Corp. v. Milgraum, 192 F.3d 1362 (Fed. Cir.) (distinguishing occasional/possible results from inherent, natural results)